Xia Yang, PhD

• Experienced project manager skillful of interdisciplinary collaboration, strategic planning and achieving business result.
• Seasoned biotechnology professional with well-rounded technical and operational expertise advancing innovative small molecule, biologic and gene therapy from research to clinical development.

Reading, Journaling, Volunteer, Golf, Yoga, Marathon, Tennis, Travel

https://www.linkedin.com/in/xiavyang/

• Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Huang X, Magnus J, Kaimal V, Karmali P, Li J, Walls M, Prudente R, Sung E, Sorourian M, Lee R, Davis S, Yang X, Estrella H, Lee EC, Chau BN, Pavlicek A, Zabludoff S Mol Cancer Ther. 2017
• Apolipoprotein E Receptor 2 Mediates Activated Protein C–Induced Endothelial Akt Activation and Endothelial Barrier Stabilization Sinha RK, Yang X, Fernández JA, Xu X, Mosnier LO, Griffin JH ATVB, 2016
• Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, Yu J, Nelen MI, Liu X, Castro G, Luna R, Crawford S, Banie H, Dandridge RA, Deng X, Bittner A, Kuei C, Tootoonchi M, Rozenkrants N, Herman K, Gao J, Yang X, Sachen K, Ngo K, Fung-Leung WP, Nguyen S, de Leon-Tabaldo A, Blevitt J, Zhang Y, Cummings MD, Rao T, Mani NS, Liu C, McKinnon M, Milla ME, Fourie AM, Sun S. Proc Natl Acad Sci U S A. 2014
• Identification of structural motifs critical for epstein-barr virusinduced molecule function and homology modeling of the ligand docking site Zhang L, Shih AY, Yang X, Kuei C, Wu J, Deng X, Mani NS, Mirzadegan T, Sun S, Lovenberg TW, Liu C. Mol Pharmacol. 2012
• Oxysterols direct B-cell migration through EBI2 Liu CL, Yang X, Wu JJ, Kuei C, Mani NS, Zhang L, Yu JX, Sutton SW, Qin N, Banie H, Karlsson L, Sun SQ, Lovenberg TW.Nature. 2011
• Activated protein C ligation of ApoER2 (LRP8) causes Dab1dependent signaling in U937 cells. Yang X, Banerjee Y, Fernández JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, WhiteAdams TC, McCarty OJ, Griffin JH. Proc Natl Acad Sci U S A. 2009
• Hyper-antithrombotic, Non-cytoprotective Glu149Ala Activated Protein C Mutant Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernández JA, Yang X, Riewald M, Weiler H, Ruggeri ZM and Griffin JH. Blood. 2009
• Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activatible fibrinolysis inhibitordependent cytoprotective functions Mosnier LO, Yang X, Griffin JH. J Biol Chem. 2007
• Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C.Kerschen EJ, Fernandez JA, Cooley BC, Yang X, Sood R, Mosnier LO, Castellino FJ, Mackman N, Coughlin SR, Griffin JH & Weiler H. J Exp Med. 2007
• Identification of residues Asn89, Ile90, and Val107 of the factor IXa second epidermal growth factor domain that are essential for the assembly of the factor X-activating complex on activated platelets Yang X, Chang YJ, Lin SW, Walsh PN. J Biol Chem, 2004
• An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex Yang X and Walsh PN. Biochem J, 2005